Experimental combo targets Hard-to-Treat cancers
NCT ID NCT03994601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, and to find the right dose. The study is now complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986288 (an experimental drug) and nivolumab (Opdivo, an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial focused on safety, so it is not yet known if the drug combination works. Side effects could be serious, and the results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
Toulon, 83100, France
-
Local Institution - 0001
Hackensack, New Jersey, 07601, United States
-
Local Institution - 0002
Baltimore, Maryland, 21287, United States
-
Local Institution - 0004
St Louis, Missouri, 63110, United States
-
Local Institution - 0005
Aurora, Colorado, 80045, United States
-
Local Institution - 0006
Toronto, Ontario, M5G 2M9, Canada
-
Local Institution - 0008
ABB, Distrito Federal, C1199, Argentina
-
Local Institution - 0009
Santiago, Santiago Metropolitan, 8420383, Chile
-
Local Institution - 0010
Viña del Mar, Valparaiso, 2520598, Chile
-
Local Institution - 0011
Ciudad Autónoma de Buenos Aires, Buenos Aires, 1426, Argentina
-
Local Institution - 0012
CABA, Distrito Federal, C1430, Argentina
-
Local Institution - 0013
Río Cuarto, Córdoba Province, 5800, Argentina
-
Local Institution - 0014
Córdoba, Córdoba Province, X5000HXL, Argentina
-
Local Institution - 0015
Paris, 75248, France
-
Local Institution - 0016
Buenos Aires, C1280AEB, Argentina
-
Local Institution - 0017
Buenos Aires, 1431, Argentina
-
Local Institution - 0018
Bron, 69677, France
-
Local Institution - 0019
Santiago, Santiago Metropolitan, 7510032, Chile
-
Local Institution - 0022
Saint-Herblain, Loire-Atlantique, 44800, France
-
Local Institution - 0023
Madrid, 28041, Spain
-
Local Institution - 0024
Majadahonda, 28222, Spain
-
Local Institution - 0025
Valencia, 46026, Spain
-
Local Institution - 0026
Marseille, 13915, France
-
Local Institution - 0028
Ancona, 60126, Italy
-
Local Institution - 0031
Milan, 20162, Italy
-
Local Institution - 0033
Catanzaro, 88100, Italy
-
Local Institution - 0034
Bordeaux, Gironde, 33075, France
-
Local Institution - 0035
Santiago, Santiago Metropolitan, 7620002, Chile
-
Local Institution - 0036
Santiago, Santiago Metropolitan, 7500921, Chile
-
Local Institution - 0038
Padova, Veneto, 35128, Italy
-
Local Institution - 0039
Roma, 00168, Italy
-
Local Institution - 0040
Milan, Lombardy, 20133, Italy
-
Local Institution - 0042
Montreal, Quebec, H2X 0A9, Canada
-
Local Institution - 0046
Montreal, Quebec, H3T 1E2, Canada
-
Local Institution - 0050
Orange, California, 92868-3201, United States
-
Local Institution - 0054
Barcelona, Catalunya [Cataluña], 08036, Spain
-
Local Institution - 0055
Seville, 41013, Spain
-
Local Institution - 0056
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Local Institution - 0074
Buenos Aires, Buenos Aires F.D., C1096AAS, Argentina
-
Local Institution - 0075
Costa Mesa, California, 92627, United States